April 2016

 

In this Issue

Advances In Retina Medicine

Which emerging concepts will become part of tomorrow's practice?

  • Issue

  • Insert

  • Insert

  • Insert

  • Insert

  • Supplement

  • Supplement

  • Supplement

 

Medical Editors’ Page

Pride in Progress

By Allen C. Ho, MD, and Robert L. Avery, MD

Protocol T Year 2: What Doctors Are Saying

Two-year results from the DRCR.net’s Protocol T trial were released at the end of February. How have retina specialists reacted?

By the editors of Retina Today

BUSINESS OF RETINA

PA Avenue Updates

Down, But Not Out: How the AAO Has Responded to Medicare’s 2016 Retina Fee Cuts

Faced with cuts to retinal detachment reimbursements, the AAO sprang into action.

By George A. Williams, MD
Innovations in Retina

Understanding Blue Light

Exposure to certain wavelengths of blue light carries potential blinding effects and a link to AMD.

By Aron Shapiro
Fellows’ Focus

The Future of Retina: Emerging Technologies and Unmet Needs

Meant to be a forum for new ideas and surgical innovations, the 2016 Vail Vitrectomy meeting did not disappoint. Experts from around the globe shared their expertise and, more so, their thoughts on the future of retina and where it still needs to improve.

By M. Ali Khan, MD
Coding for Retina

Physician Supervision Conundrums

Making sense of “incident to” services and diagnostic tests.

By Riva Lee Asbell

RETINA SURGERY

Retina Pearls

A Novel IOL Rescue Technique

The technique preserves the existing IOL and avoids potential complications.

By Sumit P. Shah, MD, and Nicholas D. Chinskey, MD
Global Perspectives

Navigated Microsecond Laser for Recurrent CSCR With Subfoveal Leaks

In a case report, one laser session resolved fluid and improved visual function.

By Rohit Yogi, MD; Mahima Jhingan, MD; and Jay Chhablani, MD

MEDICAL RETINA

A Postmodern View of Anti-VEGF Treatment

Knowledge is power in treating patients with DME.

By Nancy M. Holekamp, MD

OCULAR ONCOLOGY

Uveal Melanoma in an African American Patient

A young woman with no acknowledged white non-Hispanic ancestry received a rare diagnosis.

By Kareem Sioufi, MD; Renelle Pointdujour-Lim, MD; and Carol L. Shields, MD

RETINA IMAGING

Get the Most Out of Your SD-OCT Device

A review of the features and functions of the Spectralis.

By S.K. Steven Houston III, MD

SPECIAL FOCUS: THE PATIENT PERSPECTIVE

Informed Consent and the Physician-Patient Relationship

Moving from the informative to the deliberative model.

By Arun Patel, MD, and Mya Aung, MBS, DO, MMed, Sc(Ophth)

COVER FOCUS: Advances in Retina Medicine

A Primer on Cellular Therapy

The treatment approach has taken aim at its first retinal disease: CMV retinitis.

By Mrinali Gupta, MD, and Szilárd Kiss, MD

Breakthrough Treatment Modalities for Hereditary Retinal Diseases

Options for managing patients with inherited retinal diseases are becoming more proactive.

By Hershel R. Patel, MS, MD, and David Eichenbaum, MD

Will a New Low-Cost Option Join the Anti-VEGF Fold?

An existing cancer drug could offer an alternative treatment to patients with macular diseases.

By Brian C. Joondeph, MD, MPS

Gene Therapy on the Horizon for X-Linked Retinoschisis and X-Linked RP

Insights gained from ongoing clinical programs will help guide future studies.

By David G. Birch, PhD

5Q With David R.P. Almeida, MD, MBA, PhD

David R.P. Almeida, MD, MBA, PhD, is a vitreoretinal surgeon at VitreoRetinal Surgery, PA, in Minneapolis, Minn.

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.